Current position

Joel Greenblatt’s Adaptive Biotechnologies Corp (ADPT) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Gotham Asset ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2022Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares140.76KHighest verified quarter-end share count
Quarters reported11Verified quarters with shares above zero
What happened?

Gotham Asset Management first reported Adaptive Biotechnologies Corp in Q2 2022. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Gotham Asset Management currently reports 74.73K shares. The latest verified filing showed: Sold 17.6% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 17.6% of the position−16.01K shares · 74.73K shares remained
Filing context

Quarter-end price $21.45

Q1 2026
Sold 35.5% of the position−50.01K shares · 90.75K shares remained
Filing context

Quarter-end price $13.88

Q4 2025
Bought 10.8% more+13.69K shares · 140.76K shares reported after the change
Filing context

Quarter-end price $16.24

Q3 2025
Bought 76.8% more+55.18K shares · 127.06K shares reported after the change
Filing context

Quarter-end price $14.96

Q2 2025
Bought 572.3% more+61.19K shares · 71.89K shares reported after the change
Filing context

Quarter-end price $11.65

Q1 2025
New position+10.69K shares · 10.69K shares reported
Filing context

Quarter-end price $7.43

Portfolio importance

How important is Adaptive Biotechnologies Corp in Gotham Asset Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#1217of 1791 reported positions
Peak portfolio weight0.0%Q2 2022
Best historical rank#839Q2 2022
At peak importanceQ2 2022
ADPT
0.0%
Largest holding
8.0%
Cross-investor discovery

Who else owns Adaptive Biotechnologies Corp?

Also reported by 2 other tracked investors in their latest verified filings.

Cathie WoodARK Investment Management
ADPT0.3% of reported portfolio
Ray DalioBridgewater Associates, LP
ADPT0.0% of reported portfolio
Explore Adaptive Biotechnologies Corp across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$27.672026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$21.45Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Gotham Asset Management, LLC’s Form 13F disclosures—not Joel Greenblatt’s personal brokerage account. The filing is firm-level rather than a personal stock list. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.